Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
26/06/2026 12:15
BRIEF-Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy June 26 (Reuters) - Nippon Shinyaku Co Ltd 4516.T:
ELIXIRGEN THERAPEUTICS AND NIPPON SHINYAKU ENTER INTO AN OPTION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF EXG-7001 FOR DUCHENNE MUSCULAR DYSTROPHY
ELIXIRGEN THERAPEUTICS: WILL RECEIVE UPFRONT PAYMENT, IS ELIGIBLE FOR ADDITIONAL DEVELOPMENT AND SALES-BASED MILESTONE PAYMENTS
ELIXIRGEN THERAPEUTICS: NIPPON SHINYAKU MAY OBTAIN EXCLUSIVE WORLDWIDE RIGHTS TO COMMERCIALIZE EXG-7001
ELIXIRGEN THERAPEUTICS: NIPPON SHINYAKU WILL PROVIDE FUNDING FOR DEVELOPMENTAL COSTS
Source text: ID:nGNX7W5mG0
Further company coverage: 4516.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)